Quizartinib

Gilteritinib (T4409), quizartinib (T2066) and OSI-027 (T6319) were purchased from TargetMol. Palbociclib (S1579) and rapamycin (S1039) were purchased from Selleck, abemaciclib (L190223) and Torin 1 (T129642) were obtained from Aladdin. Primary antibodies for Western blot analysis include AKT (CST, 4691S), phospho-AKT (ser47, CST, 4060S), CDK2 (CST, 2546S), Rb (Abcam, ab181616), phospho-Rb (Ser807/811, CST, 8516T), phospho-Rb (Ser780, CST, 8180T), Cyclin D1 (Abcam, ab40754), GAPDH (CST, 5174S). The anti-rabbit HRP-conjugated secondary antibodies (7074S) were obtained from CST.

Sitravatinib, gilteritinib and quizartinib were purchased from TargetMol (Boston, USA). For in vitro experiments, all the drugs were reconstituted in DMSO to 10 mM for storage and further diluted in the culture medium with the final concentration of DMSO below 0.1%. For in vivo animal experiments, gilteritinib and quizartinib were suspended in a 0.5% methylcellulose solution and sitravatinib was dissolved in a formula containing 5% DMSO, 30% PEG300, 10% Tween 80 and 55% sterile water. DMSO, methylcellulose, PEG300, Tween 80 and busulfan were provided by MedChemExpress (Monmouth Junction, USA). FL and FGF2 were provided by PeproTech (Cranbury, USA).